Lyell Immunopharma (LYEL) Price & Analysis

Compare

147 Followers

LYEL Stock Chart & Stats

$25.25

-$0.01(-1.66%)

At close: Jan 08 4:00 PM EST

$25.25

-$0.01(-1.66%)

Day’s Range― - ―

52-Week Range$7.65 - $34.43

Previous CloseN/A

Volume124.06K

Average Volume (3M)28.02K

Market Cap

$405.90M

Enterprise Value$30.12M

Total Cash (Recent Filing)$319.62M

Total Debt (Recent Filing)$44.28M

Price to Earnings (P/E)―

Beta1.54

Next Earnings

Mar 04, 2026

EPS Estimate

-2.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.13

Shares Outstanding21,218,218

10 Day Avg. Volume32,893

30 Day Avg. Volume28,022

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.44

Price to Sales (P/S)2743.40

P/FCF Ratio-1.03

Enterprise Value/Market Cap0.07

Enterprise Value/Revenue734.67

Enterprise Value/Gross Profit734.67

Enterprise Value/Ebitda-0.16

Forecast

1Y Price Target

$20.00

Price Target Upside-20.79% Downside

Rating ConsensusHold

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst UpgradeAnalyst upgrades shares of Lyell to Buy from the prior Neutral and raises the price target to $45, reflecting increased conviction following a constructive KOL call on Colorectal Cancer.

Clinical SuccessNew expert feedback confirms that Lyell's existing LYL273 dataset is already clearing the clinical high jump for success in late-line Colorectal Cancer by a wide margin.

Leadership In The FieldThe strategic reset by competitors places Kite behind Lyell, removing a primary near-term threat and affirming Lyell's leadership in the field.

Bears Say

Data LimitationsThe dataset is quite small, and durability remains immature with a limited number of events, making it difficult to support confident projections of long-term durability or commercial viability.

Safety ConcernsThe safety profile remains unproven due to a colitis-related fatality and the subsequent need for protocolized diarrhea prophylaxis.

Uncertain ProjectionsWithout more definitive durability and clearer evidence that toxicity can be reliably managed at scale, there is not yet conviction in the projections.

Lyell Immunopharma News

Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Lyell Immunopharma (LYEL) to Buy from Neutral with a price target of $45, up from...

5d ago

LYEL

Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel

Lyell Immunopharma (LYEL) announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel in...

6d ago

LYEL

Lyell Immunopharma files to sell 1.9M shares of common stock for holders

16:39 EST Lyell Immunopharma (LYEL) files to sell 1.9M shares of common stock for holders Published first on...

8d ago

LYEL

Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lyell Immunopharma (LYEL) to $20 from $10 and keeps a...

20d ago

LYEL

Lyell Immunopharma Presents Promising CAR T-Cell Data

Lyell Immunopharma ( ($LYEL) ) has shared an announcement. On December 7, 2025, Lyell Immunopharma presented promising data...

6d ago

LYEL

Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement

Lyell Immunopharma ( ($LYEL) ) has issued an announcement. On December 3, 2025, Lyell Immunopharma‘s Board of Directors...

8d ago

LYEL

Lyell Immunopharma Reports Q3 2025 Financial Results

Lyell Immunopharma, Inc. ( ($LYEL) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

LYEL

Lyell Immunopharma reports Q3 revenue $15k vs $34k last year

“Lyell is well positioned with two next-generation CAR T-cell product candidates, each with promising clinical data. We look...

1M ago

LYEL

Lyell Immunopharma acquires exclusive global rights to LYL273

Lyell Immunopharma (LYEL) announced it has strengthened its solid tumor pipeline by acquiring global rights to LYL273, a...

1M ago

LYEL

Lyell Immunopharma Secures Global Rights for LYL273

Lyell Immunopharma ( ($LYEL) ) has issued an announcement. On November 6, 2025, Lyell Immunopharma entered into an...

1M ago

LYEL

LYEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Lyell Immunopharma, Inc. (LYEL) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

1M ago

LYEL

Lyell Immunopharma Appoints New Financial Leadership Team

Lyell Immunopharma ( ($LYEL) ) just unveiled an update. On October 31, 2025, Lyell Immunopharma announced key leadership...

1M ago

LYEL

Lyell Immunopharma’s LYL314 Study: A Promising Step in Lymphoma Treatment

Lyell Immunopharma, Inc. (($LYEL)) announced an update on their ongoing clinical study. Lyell Immunopharma, Inc. is conducting a...

2M ago

LYEL

Lyell Immunopharma’s New CAR T-Cell Therapy Trial: A Potential Game-Changer in Lymphoma Treatment?

Lyell Immunopharma, Inc. (($LYEL)) announced an update on their ongoing clinical study. Lyell Immunopharma, Inc. is conducting a...

2M ago

LYEL

LYEL FAQ

What was Lyell Immunopharma’s price range in the past 12 months?

Lyell Immunopharma lowest stock price was $7.65 and its highest was $34.43 in the past 12 months.

What is Lyell Immunopharma’s market cap?

Lyell Immunopharma’s market cap is $405.90M.

When is Lyell Immunopharma’s upcoming earnings report date?

Lyell Immunopharma’s upcoming earnings report date is Mar 04, 2026 which is in 80 days.

How were Lyell Immunopharma’s earnings last quarter?

Lyell Immunopharma released its earnings results on Nov 12, 2025. The company reported -$2.13 earnings per share for the quarter, beating the consensus estimate of -$2.468 by $0.338.

Is Lyell Immunopharma overvalued?

According to Wall Street analysts Lyell Immunopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lyell Immunopharma pay dividends?

Lyell Immunopharma does not currently pay dividends.

What is Lyell Immunopharma’s EPS estimate?

Lyell Immunopharma’s EPS estimate is -2.37.

How many shares outstanding does Lyell Immunopharma have?

Lyell Immunopharma has 21,218,218 shares outstanding.

What happened to Lyell Immunopharma’s price movement after its last earnings report?

Lyell Immunopharma reported an EPS of -$2.13 in its last earnings report, beating expectations of -$2.468. Following the earnings report the stock price went down -1.248%.

Which hedge fund is a major shareholder of Lyell Immunopharma?

Currently, no hedge funds are holding shares in LYEL

Lyell Immunopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-75.75%

Trailing 12-Months

Asset Growth

-34.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lyell Immunopharma

Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies to treat cancer, particularly solid tumors. The company operates within the biopharmaceutical sector and utilizes its proprietary technology platform to engineer T cells for enhanced anti-tumor activity. Lyell's core products include a pipeline of cell therapy candidates aimed at improving the efficacy and safety of cancer treatments, leveraging advancements in immunotherapy.

Lyell Immunopharma (LYEL) Earnings & Revenues

Historic Earnings Reports

LYEL Stock 12 Month Forecast

Average Price Target

$20.00

▼(-20.79% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","11":"$11","15":"$15","19":"$19","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11,15,19,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.1,21.93846153846154,21.77692307692308,21.615384615384617,21.453846153846154,21.292307692307695,21.130769230769232,20.96923076923077,20.807692307692307,20.646153846153847,20.484615384615385,20.323076923076922,20.161538461538463,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.1,21.93846153846154,21.77692307692308,21.615384615384617,21.453846153846154,21.292307692307695,21.130769230769232,20.96923076923077,20.807692307692307,20.646153846153847,20.484615384615385,20.323076923076922,20.161538461538463,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.1,21.93846153846154,21.77692307692308,21.615384615384617,21.453846153846154,21.292307692307695,21.130769230769232,20.96923076923077,20.807692307692307,20.646153846153847,20.484615384615385,20.323076923076922,20.161538461538463,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.4,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.41,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.55,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.66,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.1,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >